NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: tipifarnib
Radiation: radiation therapy

First Posted Date: 2003-04-09

Last Posted Date: 2013-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00058097

Locations: 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States

BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: cisplatin
Drug: ixabepilone

First Posted Date: 2003-04-09

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT00057850

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer

Phase 2

Completed

Conditions: Stage IVB Cervical Cancer
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma
Recurrent Cervical Carcinoma
Stage IVA Cervical Cancer
Cervical Adenosquamous Carcinoma

Interventions: Drug: Paclitaxel
Drug: Oxaliplatin

First Posted Date: 2003-04-09

Last Posted Date: 2015-11-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00057863

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States

Perifosine in Treating Patients With Recurrent Prostate Cancer

Phase 2

Terminated

Conditions: Recurrent Prostate Cancer
Stage IIB Prostate Cancer
Stage III Prostate Cancer
Stage IV Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Drug: perifosine
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2015-02-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00058214

Locations: 🇺🇸
UC Davis Cancer Center, Sacramento, California, United States

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Stage IV Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Recurrent Prostate Cancer

Interventions: Drug: tanespimycin
Drug: docetaxel

First Posted Date: 2003-04-09

Last Posted Date: 2014-06-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00058253

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3

Phase 4

Completed

Conditions: Hepatitis C

Interventions: Drug: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2003-03-25

Last Posted Date: 2013-12-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 58

Registration Number: NCT00056862

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation

Completed

Conditions: Kidney Transplantation

First Posted Date: 2003-03-24

Last Posted Date: 2017-10-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 134

Registration Number: NCT00056784

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

Phase 1

Completed

Conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Nasopharynx
Stage IV Squamous Cell Carcinoma of the Oropharynx
Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity

Interventions: Drug: erlotinib hydrochloride
Drug: docetaxel
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-03-07

Last Posted Date: 2013-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00055770

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Phase 2

Completed

Conditions: Recurrent Gastrointestinal Carcinoid Tumor
Regional Gastrointestinal Carcinoid Tumor
Metastatic Gastrointestinal Carcinoid Tumor

Interventions: Biological: PEG-interferon alfa-2b
Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2003-03-07

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT00055809

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: tipifarnib
Drug: cisplatin
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-03-07

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00055757

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Home Terms & Conditions Privacy Policy